Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes – AstraZeneca

Written by | 3 May 2021

AstraZeneca’s Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage… read more.

Pregnant women with COVID-19 face high mortality rate

Written by | 1 May 2021

In a worldwide study of 2,100 pregnant women, those who contracted COVID-19 during pregnancy were 20 times more likely to die than those who did not contract the… read more.

UK MHRA approves Vazkepa to reduce the risk of cardiovascular events – Amarin Corp

Written by | 27 Apr 2021

Amarin Corporation announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted a Great Britain Marketing Authorisation for Vazkepa (icosapent ethyl) as a treatment to reduce… read more.

Link between lactation and visceral, pericardial fat

Written by | 15 Apr 2021

As demonstrated by multiple studies over the years, women who breastfeed have a lower risk for developing cardiovascular disease and diabetes when compared to those who don’t or… read more.

FDA approves Zegalogue for severe hypoglycemia in pediatric and adult patients with diabetes – Zealand Pharma

Written by | 8 Apr 2021

Zealand Pharma announced that the FDA has approved Zegalogue (dasiglucagon) injection for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and… read more.

Semaglutide reduces excess body fat in people with obesity

Written by | 31 Mar 2021

In adults with obesity or overweight, weekly treatment with the glucagon-like peptide 1 (GLP1) receptor agonist semaglutide leads to reduced excess body fat and increased lean body mass,… read more.

Weekly insulin helps patients with type 2 diabetes achieve similar blood sugar control to daily insulin

Written by | 30 Mar 2021

A new once-weekly basal insulin injection demonstrated similar efficacy and safety and a lower rate of low blood sugar episodes compared with a daily basal insulin, according to… read more.

Insulet’s Omnipod 5 automated insulin delivery system improves clinical outcomes in type 1 diabetes

Written by | 28 Mar 2021

Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod brand of products, announced positive results from the first pivotal trial… read more.

Type 2 diabetes is associated with increased risk of Parkinson’s

Written by | 21 Mar 2021

Research from Queen Mary University of London has concluded that there is convincing evidence that type 2 diabetes is associated with an increased risk of Parkinson’s disease. The… read more.

Semaglutide cuts body weight in at-risk obese patients

Written by | 18 Mar 2021

Article by Bruce Sylvesyter. In tandem with lifestyle management, once-weekly semaglutide therapy has enabled obese, non-diabetic patients to lose a significant amount of weight, researchers reported on Feb…. read more.

The SHAPES pilot project

Written by | 22 Feb 2021

Interview and article written by Christine Clark With advancing age many people now look forward to a future in which digital solutions will support effective self-management and independent… read more.

Obesity may exacerbate the effects of Alzheimer’s disease, new study shows

Written by | 8 Feb 2021

New research from the University of Sheffield has found being overweight is an additional burden on brain health and it may exacerbate Alzheimer’s disease.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.